Plain-English translation of NCT07522008 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The ICHARUS study is tracking patients on kidney dialysis who are receiving hemoadsorption—an add-on treatment that works alongside standard dialysis to remove more harmful waste products from the blood. Many people on dialysis still experience bothersome symptoms like severe itching, fatigue, and poor sleep even with good dialysis care, and this study is observing whether adding hemoadsorption helps relieve those symptoms.
Standard dialysis removes some waste products well, but it may not be effective enough at removing certain toxins that build up in the blood and cause uncomfortable symptoms. This study exists to understand whether this additional blood-cleaning technique can help dialysis patients feel better and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
You will continue receiving your regular dialysis treatment, now with the added hemoadsorption technique—this change is based on your doctor's clinical decision, not the study itself. You will be asked to complete questionnaires about your symptoms and how you are feeling at regular intervals, and your medical information and treatment details will be collected as part of the study registry. There are no extra procedures or tests required beyond your normal dialysis care and routine check-ups.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Italy